Cargando…

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma

SIMPLE SUMMARY: Cartilage tumors frequently harbor mutations in the isocitrate dehydrogenase (IDH1 or IDH2) genes. These mutations cause an increase in the levels of the oncometabolite D-2-hydroxyglutarate (D-2-HG), which leads to widespread changes in several cellular processes, including the epige...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venneker, Sanne, Kruisselbrink, Alwine B., Baranski, Zuzanna, Palubeckaite, Ieva, Briaire-de Bruijn, Inge H., Oosting, Jan, French, Pim J., Danen, Erik H. J., Bovée, Judith V. M. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760027/ https://www.ncbi.nlm.nih.gov/pubmed/33266275 http://dx.doi.org/10.3390/cancers12123589

Ejemplares similares

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
por: Venneker, Sanne, et al.
Publicado: (2019)

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes
por: de Jong, Yvonne, et al.
Publicado: (2019)

Selection of Effective Therapies Using Three-Dimensional in vitro Modeling of Chondrosarcoma
por: Palubeckaitė, Ieva, et al.
Publicado: (2020)

IDH Mutations in Chondrosarcoma: Case Closed or Not?
por: Venneker, Sanne, et al.
Publicado: (2023)

SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone
por: Kroonen, Jessie S., et al.
Publicado: (2021)

Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression
por: Franceschini, Natasja, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone
por: Venneker, Sanne, et al.
Publicado: (2022)

A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target
por: Franceschini, Natasja, et al.
Publicado: (2021)

A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival
por: de Jong, Yvonne, et al.
Publicado: (2019)

Targeting survivin as a potential new treatment for chondrosarcoma of bone
por: de Jong, Y, et al.
Publicado: (2016)

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
por: Suijker, Johnny, et al.
Publicado: (2015)

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
por: Peterse, Elisabeth F. P., et al.
Publicado: (2018)

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
por: Cleven, Arjen H. G., et al.
Publicado: (2017)

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone
por: Peterse, Elisabeth F. P., et al.
Publicado: (2016)

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
por: Addie, Ruben D., et al.
Publicado: (2019)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma
por: Venneker, Sanne, et al.
Publicado: (2019)

IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
por: Lugowska, Iwona, et al.
Publicado: (2018)

IMMUNOHISTOCHEMICAL ANALYSIS BY KI67 AND IDH1 IN PATIENTS WITH CHONDROSARCOMA
por: RIBEIRO, MARCELO BARBOSA, et al.
Publicado: (2023)

Epigenetic Abnormalities in Chondrosarcoma
por: Bereza, Michał, et al.
Publicado: (2023)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth
por: Li, Luyuan, et al.
Publicado: (2020)

Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes
por: Pathmanapan, Sinthu, et al.
Publicado: (2021)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
por: Nakagawa, Makoto, et al.
Publicado: (2022)

Chondrosarcoma: biology, genetics, and epigenetics
por: Chow, Warren A
Publicado: (2018)

Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option
por: Willems, Stefan M, et al.
Publicado: (2010)

Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta‐analysis
por: Vuong, Huy Gia, et al.
Publicado: (2021)

Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma
por: Dermawan, Josephine Kam Tai, et al.
Publicado: (2023)

Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin
por: Yang, Tingting, et al.
Publicado: (2020)

Somatic mosaic IDH1 or IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome
por: Pansuriya, Twinkal C., et al.
Publicado: (2011)

Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours
por: Cleven, Arjen H. G., et al.
Publicado: (2022)

Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation
por: Pathmanapan, Sinthu, et al.
Publicado: (2023)

Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma
por: Lam, Suk Wai, et al.
Publicado: (2019)

Clonal Evolution through Loss of Chromosomes and Subsequent Polyploidization in Chondrosarcoma
por: Olsson, Linda, et al.
Publicado: (2011)

Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas
por: van IJzendoorn, David G. P., et al.
Publicado: (2019)

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone
por: van Oosterwijk, Jolieke G, et al.
Publicado: (2012)

Correction: Clonal Evolution through Loss of Chromosomes and Subsequent Polyploidization in Chondrosarcoma
por: Olsson, Linda, et al.
Publicado: (2011)

IDH1: Linking Metabolism and Epigenetics
por: Raineri, Silvia, et al.
Publicado: (2018)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

An activating germline IDH1 variant associated with a tumor entity characterized by unilateral and bilateral chondrosarcoma of the mastoid
por: Blackburn, Patrick R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vf46ukiau6cqgjnukt8ccns6a5